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Abstract
Aims Statins improve survival and reduce rejection and cardiac allograft vasculopathy after heart transplantation (HT). The
impact of different statin intensities on clinical outcomes has never been assessed. We set out to determine the impact of
statin exposure on cardiovascular outcomes after HT.
Methods and results We performed a retrospective study of 346 adult patients who underwent HT from 2006 to 2018.
Statin intensity was determined longitudinally after HT based on American College of Cardiology/American Heart Association
(ACC/AHA) guidelines. The primary outcome was the time to the first primary event defined as the composite of heart failure
hospitalization, myocardial infarction, revascularization, and all-cause mortality. Secondary outcomes included time to signif-
icant rejection and time to moderate–severe cardiac allograft vasculopathy. Adverse events were evaluated for subjects on
high-intensity statin therapy. A Cox proportional hazards model was used to evaluate the relationship between clinical vari-
ables, statin intensity, and outcomes. Most subjects were treated with low-intensity statin therapy although this declined from
89.9% of the population at 1month after HT to 42.8% at 5years after HT. History of ischaemic cardiomyopathy, significant
acute rejection, older donor age, and lesser statin intensity (p ≤ 0.001) were associated with reduced time to the primary out-
come in a multivariable Cox model. Greater intensity of statin therapy was most beneficial early after HT. There were no
statin-related adverse events for the 14 subjects on high-intensity statin therapy.
Conclusions Greater statin intensity was associated with a reduction in adverse cardiovascular outcomes after HT.
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Introduction
Treatment with HMG CoA reductase inhibitors (statins) is rec-
ommended early after heart transplantation (HT),1 as data
support improved survival and reduced rejection and cardiac
allograft vasculopathy (CAV) in statin-treated HT recipients.2–
8 While statins lower low-density lipoprotein cholesterol (LDL-
C), there is evidence for additional non-LDL-C-lowering ef-
fects in cell culture and animal studies.9 This is supported in-
directly in clinical trials,10,11 with statins having potentially
dose-dependent effects on inflammatory biomarkers.12
Despite evidence for statins’ beneficial effects, both
through LDL-C-lowering and through non-LDL-C-lowering
mechanisms, their use has been limited in some popula-
tions by dose-dependent drug–drug interactions, most no-
tably with cyclosporine in transplant recipients.13 As a
result, studies in this population have only evaluated the
efficacy of low-intensity or moderate-intensity statin ther-
apy, most often in comparison with no statin.2,3,5,6,14 Cur-
rent transplant guidelines recommend treatment with a
lesser intensity statin than that used traditionally for man-
agement of hyperlipidaemia or coronary artery disease.1
Limited data, however, now support the safety of
high-intensity statin therapy in patients treated with
tacrolimus-based immunosuppression, the current standard
of care after HT.15,16
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We performed a retrospective chart review of HT recipi-
ents to determine the impact of statin intensity, assessed lon-
gitudinally, on clinical outcomes. We secondarily evaluated
the impact of statin intensity on rejection and CAV. We hy-
pothesized that greater intensity of statin therapy would be
associated with prolonged time to our primary composite
endpoint of heart failure (HF) hospitalization, revasculariza-
tion, myocardial infarction (MI), or death and that the impact
of statin therapy on clinical outcomes would be greatest early
after HT.
Methods
Study design and patient selection
We retrospectively identified patients older than 18 who
underwent a first HT at the University of Michigan between
January 2006 and March 2018. Patients who died within
30 days of HT or who were managed by Pediatric Cardiology
were excluded. Last follow-up was June 2018. Information
was collected through chart review on patient demographics;
co-morbid conditions; medications; post-transplant coronary
angiograms, echocardiograms, and positron emission tomog-
raphy (PET) scans; rejection history; and all lipid levels
after HT. The PET imaging protocol has previously been
published.17 The study was approved by the University of
Michigan Institutional Review Board and is in compliance with
the Declaration of Helsinki. Informed consent was waived
given the retrospective nature of this work.
Determination of statin intensity
The prescribed statin and dose were extracted from the med-
ical record at 1month, 3months, 6 months, 1year, and 5years
after HT. At each time point, subjects were categorized as
being on no statin or on low-intensity, moderate-intensity,
or high-intensity statin therapy as defined by the 2013
ACC/AHA Guidelines (Supporting Information, Table S1).18
Timepoints in which subjects were on no statin were assigned
scores of 0 while timepoints in which subjects were on low-
intensity, moderate-intensity, or high-intensity statin therapy
were assigned scores of 1, 2, or 3, respectively.
Given the established safety of low-intensity and
moderate-intensity statin therapy in transplant recipients,2–8
we evaluated for elevations in serum aspartate transferase,
alanine transferase, or creatinine kinase levels and for myal-
gias or rhabdomyolysis during treatment with high-intensity
statin therapy. The clinical context surrounding statin discon-
tinuation and all dose adjustments were reviewed.
Post-transplant protocols
At our centre, initial immunosuppression (a calcineurin inhib-
itor, mycophenolate mofetil, and prednisone) and statin ther-
apy (pravastatin 20mg daily) are protocol driven. Subsequent
drug therapy and evaluation for transplant vasculopathy with
either noninvasive testing or coronary angiography with in-
travascular ultrasound (recommended annually regardless of
perceived risk) are at the discretion of the treating transplant
cardiologist.
Clinical events
Outcomes were adjudicated by two cardiologists after chart
review. HF hospitalization was defined as signs/symptoms
of HF with at least one of the following criterion on or during
admission in the absence of another aetiology: abnormal
haemodynamics, requirement for intravenous diuresis, or de-
cline in ejection fraction. Haemodynamically significant HF
during index admission for HT was considered early graft
failure. Admission for intravenous diuresis in the first 90 days
after HT not associated with rejection was considered
post-operative diastolic dysfunction and not a HF hospitaliza-
tion. MIs were defined as ST-elevation MIs or type I non-ST-
elevation MIs.
Rejection was defined according to the 2004 revised Inter-
national Society for Heart and Lung Transplantation (ISHLT)
criteria.19 Significant rejection was defined as 2R or 3R cellu-
lar rejection, any antibody-mediated rejection, or haemody-
namically significant, biopsy-negative rejection. Angiographic
CAV was defined according to ISHLT nomenclature.20
Moderate–severe CAV was defined as ISHLT CAV2 or CAV3
which requires at least one obstructive lesion in the proximal
or middle third of either the left anterior descending, left cir-
cumflex, or right coronary artery or ISHLT CAV1 with allograft
dysfunction or restrictive physiology.
Primary and secondary outcomes
The primary outcome was the time to the first primary event
defined as the composite of HF hospitalization, MI, revascu-
larization, or all-cause mortality. We included HF hospitaliza-
tions as a primary event as progressive CAV contributes to
myocardial dysfunction that increases risk for HF. Secondary
outcomes included time to (i) significant rejection, (ii)
moderate–severe CAV by ISHLT criteria, or (iii) clinical CAV,
defined as the composite of myocardial flow reserve <2 on
rest-stress rubidium-82 PET imaging, coronary revasculariza-
tion, MI, or moderate–severe CAV on coronary angiography
as above.
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Statistical analysis
Data were evaluated for normality and summarized as
mean ± standard deviation or median [25th, 75th percentile]
for continuous variables and count (%) for categorical vari-
ables, as appropriate. Kendall’s tau-b correlation coefficient
was used to assess the association between statin intensity
and LDL-C longitudinally. Univariable models identified candi-
date variables for the stepwise multivariable Cox regression
model. Cox proportional hazards models were constructed
for our primary and secondary outcomes including clinical vari-
ables as fixed covariates and first significant rejection episode
and statin intensity as time-dependent covariates. For models
violating the proportional hazards assumption, an interaction
term with time was added to account for non-proportional
hazards. For all multivariable analyses, a two-sided P-value
<0.05 was considered significant. All statistical analyses were
performed in SAS version 9.4 (SAS Institute, Cary, NC) and R ver-
sion 3.5.1 (R Foundation for Statistical Computing).
Results
Patient characteristics
From January 2006 until March 2018, 356 adult patients
underwent a first HT at the University of Michigan. Ten
patients were excluded: six died within 30days of HT second-
ary to early graft failure, and four were managed by Pediatric
Cardiology. A total of 346 subjects were included in the final
analysis. Most were male (78%) and White (81%) with a me-
dian age of 55.0 [46.0, 62.0] years at the time of HT. Twenty
subjects underwent dual heart/kidney transplant. Immuno-
suppression at 1 year included tacrolimus for 91.6%, myco-
phenolate mofetil for 74.3%, prednisone for 69.7%, and a
proliferation signal inhibitor for 2.9%. Average LDL-C pre-HT
was 81.5mg/dL ± 31.9. Subjects with higher LDL-C levels were
treated with greater intensity statin therapy (Kendall tau-
b = 0.152; P < 0.0001), presumably due to a perceived higher
risk of adverse cardiovascular outcomes after HT. Clinical
characteristics by statin intensity 1month after HT are
displayed in Table 1.
Statin therapy
The majority of subjects were treated with pravastatin. At
1month post-transplant, 97.3% of subjects were treated with
pravastatin, declining to 73.0% at 5years post-transplant
(Supporting Information, Figure S1). The remaining subjects
were treated with atorvastatin, rosuvastatin, or simvastatin.
Initially, most subjects were treated with low-intensity
statin therapy although this declined from 89.9% of the
population at 1month after HT to 42.8% at 5years after HT




intensity (n = 20)
No statin
(n = 15)
Median (IQR) Count (%) Median (IQR) Count (%) Median (IQR) Count (%)
Demographics
Patient age at transplant, years 54.0 (46.0–61.0) 60.5 (42.8–63.3) 60.0 (41.0–63.5)
Male gender 239 (76.8) 19 (95.0) 13 (86.7)
Race
White 254 (81.7) 15 (75.0) 12 (80.0)
Black 52 (16.7) 4 (20.0) 1 (6.7)
Other 5 (1.6) 1 (5.0) 2 (13.3)
Co-morbid conditions at time of transplant
Body mass index, kg/m2 27.8 (23.5–30.2) 26.9 (24.5–29.6) 23.7 (22.2–29.3)
Diabetes mellitus 108 (34.7) 4 (20.0) 4 (26.7)
Hypertension 185 (59.5) 12 (60.0) 5 (33.3)
eGFR < 60 mL/min/1.73 m2) 132 (42.6) 9 (45.0) 7 (50.0)
Transplant characteristics
Ischaemic cardiomyopathy 96 (30.9) 10 (50.0) 5 (33.3)
Organ
Heart 293 (94.2) 20 (100) 13 (86.7)
Heart/kidney 18 (5.8) 0 (0.0) 2 (13.3)
Donor age, years 32.0 (23.0–43.0) 40.0 (29.5–43.3) 44.0 (33.5–51.0)
CMV status
Donor (+)/Recipient (+) 96 (30.9) 5 (25.0) 3 (20.0)
Donor ()/Recipient () 63 (20.3) 7 (35.0) 3 (20.0)
Donor (+)/Recipient () 72 (23.2) 7 (35.0) 6 (40.0)
Donor ()/Recipient (+) 80 (25.7) 1 (5.0) 3 (20.0)
Ischaemic time, min 160.0 (125.5–191.0) 154.0 (117.5–186.5) 151 (114.0–205.0)
Twenty subjects were treated at 1-month post-transplant with moderate-intensity or high-intensity statin therapy of which 19 were
treated with a moderate-intensity statin and 1 a high-intensity statin. CMV, cytomegalovirus; eGFR, estimated glomerular filtration rate;
IQR, interquartile range.
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(Figure 1; Table 1). At 5years, 40.0% were treated with
moderate-intensity statin therapy. Few subjects were treated
with high-intensity statin therapy, with a maximum of 5.6% of
subjects at 5years after HT. Changes in statin dose and inten-
sity were frequent over subjects’ clinical courses with the ma-
jority of subjects experiencing an increase in statin intensity
over time. Fifty subjects (14.8%) experienced a change in
statin intensity between 1month and 3months, 44 subjects
(13.4%) a change between 3 months and 6months, 44 sub-
jects (14.1%) a change between 6months and 1year, and 56
subjects (31.1%) a change between 1year and 5years.
Primary outcome
One hundred six (106) of the 346 subjects experienced at
least one of the primary events. The first event was HF hospi-
talization for 56 subjects (52.8%), revascularization or MI for
7 subjects (6.6%), and death for 43 subjects (40.6%). In an
unadjusted Cox regression model, significant acute rejection
(as defined in the text), older donor age, and lesser statin in-
tensity were associated with reduced time to the primary
composite outcome (Table 2). Since statin intensity failed
the proportional hazards assumption, an adjusted model
was created in which an interaction term was added between
statin intensity and time. In the final semi-parametric model,
history of ischaemic cardiomyopathy, significant acute rejec-
tion, older donor age, and lesser statin intensity were all asso-
ciated with reduced time to the primary composite outcome
(Table 3). Greater intensity statin therapy was most beneficial
early after HT.
FIGURE 1 Statin intensity by time. The majority of subjects were treated with low-intensity statin therapy after heart transplant, although this declined
over time in favour of treatment with moderate-intensity statin therapy. Few subjects were treated with high-intensity statin therapy.
Table 2 Univariable Cox model for time to heart failure hospitali-








Patient age at transplant,
years
1.006 0.990–1.022 0.490
Male gender 1.175 0.729–1.896 0.500
Race (ref = white)
Black 1.101 0.669–1.812 0.705
Other 0.455 0.063–3.272 0.434
Body mass index, kg/m2 1.031 0.990–1.074 0.139
Transplant characteristics
Ischaemic cardiomyopathy 1.346 0.911–1.988 0.136
Donor age, years 1.020 1.004–1.036 0.013
CMV status [ref = Donor (+)/Recipient (+)]
Donor ()/Recipient () 1.065 0.609–1.864 0.824
Donor (+)/Recipient () 1.060 0.618–1.819 0.832
Donor ()/Recipient (+) 1.376 0.825–2.296 0.221
CMV infection 1.359 0.744–2.483 0.318
Ischaemic time, min 1.002 0.997–1.007 0.393
History acute rejection 2.150 1.447–3.194 <.001
Statin intensity 0.659 0.479–0.905 0.010
CMV, cytomegalovirus; ref, reference.
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Rejection
Eighty-nine (89) of the 346 subjects experienced a significant
rejection episode. No clinical covariates were associated with
time to rejection in univariable or multivariable Cox regres-
sion models (Supporting Information, Table S2).
Cardiac allograft vasculopathy
One hundred seventy-five (175) subjects underwent at least
one coronary angiogram post-transplant of which 18 had ev-
idence of ISHLT CAV2 or CAV3. Moderate–severe CAV was
first documented on coronary angiography 4.36 [1.91, 5.52]
years after HT. Older donor age was associated with reduced
time to moderate–severe CAV in univariable and multivari-
able analyses (HR 1.05; 95% CI 1.01–1.09; Supporting Infor-
mation, Table S3).
Finally, we evaluated time to clinical CAV; 233 subjects had
an assessment for CAV by either angiography or PET imaging.
Seventy-six (76) of the 233 subjects experienced the compos-
ite outcome, which was driven by a myocardial flow reserve
<2 in 58 subjects (76.3%), angiographic CAV in 14 subjects
(18.4%), and revascularization or MI in 4 subjects (5.3%). Of
the 58 subjects without a coronary angiogram, 27 had CAV di-
agnosed on PET imaging. Median time to event was 4.75
[2.81, 7.14] years after HT. Older donor age was associated
with reduced time to moderate–severe CAV in univariable
and multivariable analyses (HR 1.02; 95% CI 1.01–1.04;
Supporting Information, Table S4).
Adverse events
Fourteen (14) subjects were treated with high-intensity statin
therapy: 4 subjects were on high-intensity rosuvastatin, and
10 on high-intensity atorvastatin. Thirteen (13) subjects were
concomitantly receiving tacrolimus, and 1 subject was treated
with cyclosporine (with atorvastatin). No subject experienced
myalgias, myositis, rhabdomyolysis, or hepatotoxicity attrib-
utable to high-intensity statin therapy. Ten (10) subjects
remained on high-intensity therapy once initiated, and 4 sub-
jects underwent a dose reduction during clinical follow-up. In
three cases, the rationale for the dose change was not docu-
mented, although there were no concomitant laboratory ab-
normalities. In one subject, the statin dose was decreased
after a cytomegalovirus infection lead to an elevation in se-
rum transaminase levels.
Discussion
Current guidelines support initiation of statin therapy early
after HT although at doses “lower than those recommended
for [treatment of] hyperlipidemia” due to concern for phar-
macological interactions with calcineurin inhibitors.1,13 While
the interaction between statins and cyclosporine is well doc-
umented, there is a paucity of data on the interaction be-
tween statins and tacrolimus,13 and limited data suggest
that tacrolimus and statins may be safe in combination.15,16
Furthermore, no studies have explored the incremental effi-
cacy of treatment with moderate-intensity or high-intensity
statin therapy compared with low-intensity statin therapy,
and the importance of treatment timing is unknown.
In this retrospective evaluation of the impact of longitudi-
nal statin exposure after HT, greater statin intensity signifi-
cantly prolonged time to our primary composite endpoint
of HF hospitalization, revascularization, MI, or death. Greater
statin intensity was most protective early after HT. Impor-
tantly, while only 14 patients were treated with
high-intensity statin therapy, no adverse events were ob-
served in this cohort treated predominantly with
tacrolimus-based immunosuppression.
Prior studies have shown that statin therapy reduces
cardiovascular events and mortality following HT. In the land-
mark study by Kobashigawa et al., 97 subjects were random-
ized to pravastatin 40mg daily or to no statin.6 At 1year,
subjects on pravastatin had significantly less haemodynami-
cally significant rejection, better survival, and a lower inci-
dence of CAV, the benefits of which were sustained at
10 years.14 Similar results were seen on 1year and 8years
follow-up of 72 subjects randomized to simvastatin 20mg
daily versus dietary therapy.2,5 Only one study compared
two different statins prospectively although it evaluated
low-intensity simvastatin to low-intensity pravastatin.3 While
these and other studies established the benefit of statin ther-
apy after HT, they most often compared low-intensity or
moderate-intensity statin therapy to no statin, and none eval-
uated the safety and efficacy of high-intensity statin
therapy.4–6,8
This study adds to the literature in that we evaluated the
comparative effectiveness of statin exposure (intensity and
Table 3 Multivariable Cox proportional hazards model for time to









Donor age 1.0188 1.0032–1.0347 0.0184
History acute rejection 2.3160 1.5527–3.4545 <0.0001
Statin intensity 0.3552 0.2069–0.6099 0.0002
Time × Statin intensity 1.0004 1.0001–1.0007 0.0105
History of ischaemic cardiomyopathy, acute rejection, older donor
age, and lesser statin intensity were associated with reduced time
to the primary outcome in a multivariable model. As evidenced
by the interaction between time and statin intensity, greater inten-
sity of statin therapy was most beneficial early after transplant.
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duration over time) on clinical outcomes. To fully understand
the benefits of statin therapy after HT, more comprehensive
mechanistic evaluations of CAV are necessary, including as-
sessments of coronary vascular dysfunction, a precursor to
anatomic changes to the coronary vasculature.21–24 Addition-
ally, further studies are necessary to determine the extent
to which statins act through LDL-C-lowering or through
immunomodulatory mechanisms.6,25–27 In a recent study,
pre-operative treatment of cardiac donors with simvastatin
significantly reduced recipient plasma inflammatory cytokine
levels post-operatively, altered myocardial gene transcript
signatures, and reduced treated episodes of haemodynami-
cally significant rejection.28 This suggests that very early
statin therapy may have long-lasting effects on graft function,
allorecognition, and immune responses that are consistent
with the beneficial effects we observed after early treatment
with a greater intensity statin.
Despite promising results, our study should be interpreted
in the context of its limitations. First, the study was a single-
centre, observational study. Thus, there could be unmea-
sured differences between subjects who received more ver-
sus less intensive statin therapy. We believe, however, that
subjects receiving a more intense statin may be those with
greater perceived risk for clinical events. Thus, the benefits
we observed with treatment occurred despite these individ-
uals’ potentially higher risk. Second, while statin intensity
was evaluated at 5 time points to determine statin exposure,
subjects may have undergone additional dose changes not
captured in our chart review. This would affect all subjects
equally, however, resulting in non-differential bias that would
be unlikely to significantly impact the results. Third, only 233
subjects underwent evaluations for CAV by either PET
imaging or coronary angiography, and angiography cannot
evaluate for microvascular CAV. Thus, our ability to detect
differences in time to moderate–severe CAV was limited.
The additional subjects underwent alternative assessments
for CAV including dobutamine stress echocardiograms or sin-
gle photon emission computed tomography perfusion imag-
ing. Because these modalities are less quantitative and thus
less frequently used at our centre for assessment of CAV,
we did not include the results of these tests in our analyses.
Next, we did not include LDL-C in our Cox regression
model as statin intensity and LDL-C were confounded in ex-
ploratory analyses (i.e. patients with the highest lipid levels
were treated with a greater intensity statin). Additionally,
we did not account for other medications in our analyses
aside from immunosuppressant therapy. This includes other
lipid-lowering therapies as they were used rarely in our
cohort, presumably because they are not recommended
by HT guidelines and have potentially lesser effects on
endothelial function and vascular inflammation.29,30 By not
accounting for additional medications, we recognize that
other drug interactions with statins could have been present;
however, their impact on statin levels is highly variable
and cannot be reliably predicted.13 Finally, consistent with
past and current guidelines, very few subjects were treated
with high-intensity statin therapy. Thus, the results were
driven overwhelmingly by subjects on low-intensity or
moderate-intensity statin therapy. Future studies will be nec-
essary to determine the safety and efficacy of high-intensity
statin therapy on clinical outcomes, CAV, and rejection.
In conclusion, in a single-centre study of subjects after
HT, greater statin intensity prolonged time to HF hospitaliza-
tion, revascularization, MI, or death. Greater statin intensity
conferred the largest benefit early after HT. While few sub-
jects were treated with high-intensity statin therapy, we ob-
served no adverse events in this cohort. Future studies are
needed to explore the safety and incremental efficacy of
high-intensity statin therapy after HT.
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Figure S1. Statin treatment by time. The majority of subjects
were treated pravastatin after heart transplant though this
declined with time since transplant in favour of atorvastatin,
rosuvastatin, and simvastatin.
Table S1. Statin Intensity as Defined by ACC/AHA Guidelines.1
Table abbreviated to include only statins prescribed for this
cohort. Key: mg = milligrams
Table S2. Univariable Cox proportional hazards model for
time to significant rejection. No clinical covariates were signif-
icantly associated with time to rejection (n=346). Key: CMV =
cytomegalovirus; kg = kilogram; ref = reference.
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Table S3. Univariable Cox proportional hazards model for
time to moderate-severe CAV. Only older donor age was as-
sociated with reduced time to moderate-severe CAV on coro-
nary angiography (n = 175). Key: CAV = cardiac allograft
vasculopathy; CMV = cytomegalovirus; kg = kilogram; ref =
reference.
Table S4. Univariable Cox proportional hazards model for
time to clinical CAV. Clinical CAV was defined as the
composite of PET-derived MFR <2, revascularization, myocar-
dial infarction, or ISHLT CAV2 or CAV3 on coronary angiogra-
phy. Older donor age was associated with reduced time to
clinical CAV (n=233). Key: CAV = cardiac allograft vasculopa-
thy; CMV = cytomegalovirus; kg = kilogram; MFR = myocardial
flow reserve; PET = positron emission tomography; ref =
reference.
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